The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: A prospective validation study

Hepatology

Volumn 64, Issue 6, 2016, Pages 2077-2088

  Sapisochin, Gonzalo ^a   Goldaracena, Nicolas ^a   Laurence, Jerome M ^a   Dib, Martin ^a   Barbas, Andrew ^a   Ghanekar, Anand ^a   Cleary, Sean P ^a   Lilly, Les ^a,b   Cattral, Mark S ^a   Marquez, Max ^a   Selzner, Markus ^a,b   Renner, Eberhard ^a,b   Selzner, Nazia ^a,b   McGilvray, Ian D ^a,b   Greig, Paul D ^a,b   Grant, David R ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; SORAFENIB;

ADULT; ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL OUTCOME; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; GRAFT SURVIVAL; HUMAN; HUMAN TISSUE; INTENTION TO TREAT ANALYSIS; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROSPECTIVE STUDY; STEREOTACTIC BODY RADIATION THERAPY; SURVIVAL RATE; TUMOR BIOPSY; TUMOR SEEDING; VALIDATION STUDY; CARCINOMA, HEPATOCELLULAR; LIVER NEOPLASMS; PATIENT SELECTION;

CARCINOMA, HEPATOCELLULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PATIENT SELECTION; PROSPECTIVE STUDIES;

EID: 84977068178     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.28643     Document Type: Article

References (34)

1. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012;31:1245-1255.
2. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-699.
3. Yao FY, Xiao L, Bass NM, Kerlan R, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant 2007;7:2587-2596.
4. Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, et al. Metroticket Investigator Study Group. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009;10:35-43.
5. Toso C, Meeberg G, Hernandez-Alejandro R, Dufour JF, Marotta P, Majno P, et al. Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: a prospective validation. Hepatology 2015;62:158-165.
6. Cillo U, Vitale A, Bassanello M, Boccagni P, Brolese A, Zanus G, et al. Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma. Ann Surg 2004;239:150-159.
7. de Lope CR, Tremosini S, Forner A, Reig M, Bruix J. Management of HCC. J Hepatol 2012;56(Suppl. 1):S75-S87.
8. DuBay D, Sandroussi C, Sandhu L, Cleary S, Guba M, Cattral MS, et al. Liver transplantation for advanced hepatocellular carcinoma using poor tumor differentiation on biopsy as an exclusion criterion. Ann Surg 2011;253:166-172.
9. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-1022.
10. Sandroussi C, Dawson LA, Lee M, Guindi M, Fischer S, Ghanekar A, et al. Radiotherapy as a bridge to liver transplantation for hepatocellular carcinoma. Transpl Int 2010;23:299-306.
11. Sapisochin G, Goldaracena N, Astete S, Laurence JM, Davidson D, Rafael E, et al. Benefit of treating hepatocellular carcinoma recurrence after liver transplantation and analysis of prognostic factors for survival in a large Euro-American series. Ann Surg Oncol 2015;22:2286-2294.
12. Serrano PE, Cleary SP, Dhani N, Kim PT, Greig PD, Leung K, et al. Improved long-term outcomes after resection of pancreatic adenocarcinoma: a comparison between two time periods. Ann Surg Oncol 2015;22:1160-1167.
13. Schlansky B, Chen Y, Scott DL, Austin D, Naughler WE. Waiting time predicts survival after liver transplantation for hepatocellular carcinoma: a cohort study using the united network for Organ Sharing Registry. Liver Transpl 2014;20:1045-1056.
14. Volk ML, Vijan S, Marrero JA. A novel model measuring the harm of transplanting hepatocellular carcinoma exceeding Milan criteria. Am J Transplant 2008;8:839-846.
15. Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. OLT for HCC Consensus Group. Lancet Oncol 2012;13:e11-e22.
16. Taouli B, Krinsky GA. Diagnostic imaging of hepatocellular carcinoma in patients with cirrhosis before liver transplantation. Liver Transpl 2006;12(Suppl. 2):S1-S7.
17. Decaens T, Roudot-Thoraval F, Badran H, Wolf P, Durand F, Adam R, et al. Impact of tumour differentiation to select patients before liver transplantation for hepatocellular carcinoma. Liver Int 201;36:792-801.
18. Kenmochi K, Sugihara S, Kojiro M. Relationship of histologic grade of hepatocellular carcinoma (HCC) to tumor size, and demonstration of tumor cells of multiple different grades in single small HCC. Liver 1987;7:18-26.
19. Friemel J, Rechsteiner M, Frick L, Böhm F, Struckmann K, Egger M, et al. Intratumor heterogeneity in hepatocellular carcinoma. Clin Cancer Res 2015;21:1951-1961.
20. Colecchia A, Scaioli E, Montrone L, Vestito A, Di Biase AR, Pieri M, et al. Pre-operative liver biopsy in cirrhotic patients with early hepatocellular carcinoma represents a safe and accurate diagnostic tool for tumour grading assessment. J Hepatol 2011;54:300-305.
21. Silva MA, Hegab B, Hyde C, Guo B, Buckels JA, Mirza DF. Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut 2008;57:1592-1596.
22. Fuks D, Cauchy F, Fusco G, Paradis V, Durand F, Belghiti J. Preoperative tumour biopsy does not affect the oncologic course of patients with transplantable HCC. J Hepatol 2014;61:589-593.
23. Cabibbo G, Enea M, Attanasio M, Bruix J, Craxì A, Cammà C. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology 2010;51:1274-1283.
24. Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso M, Sala M, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999;29:62-67.
25. Reig M, Bruix J. Pattern of tumor progression in liver cancer: the missing partner in trial design. Hepatology 2015;62:674-676.
26. Chevret S, Trinchet JC, Mathieu D, Rached AA, Beaugrand M, Chastang C. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. J Hepatol 1999;31:133-141.
27. Diouf M, Filleron T, Barbare JC, Fin L, Picard C, Bouche O, et al. The added value of quality of life (QoL) for prognosis of overall survival in patients with palliative hepatocellular carcinoma. J Hepatol 2013;58:509-521.
28. Yao FY, Mehta N, Flemming J, Dodge J, Hameed B, Fix O, et al. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology 2015;61:1968-1977.
29. Kim DJ, Clark PJ, Heimbach J, Rosen C, Sanchez W, Watt K, et al. Recurrence of hepatocellular carcinoma: importance of mRECIST response to chemoembolization and tumor size. Am J Transplant 2014;14:1383-1390.
30. Cillo U, Vitale A, Grigoletto F, Gringeri E, D'Amico F, Valmasoni M, et al. Intention-to-treat analysis of liver transplantation in selected, aggressively treated HCC patients exceeding the Milan criteria. Am J Transplant 2007;7:972-981.
31. Salvalaggio PR, Felga G, Axelrod DA, Della Guardia B, Almeida MD, Rezende MB. List and liver transplant survival according to waiting time in patients with hepatocellular carcinoma. Am J Transplant 2015;15:668-677.
32. Halazun KJ, Patzer RE, Rana AA, Verna EC, Griesemer AD, Parsons RF, et al. Standing the test of time: outcomes of a decade of prioritizing patients with hepatocellular carcinoma, results of the UNOS natural geographic experiment. Hepatology 2014;60:1957-1962.
33. Hameed B, Mehta N, Sapisochin G, Roberts JP, Yao FY. Alpha-fetoprotein level >1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria. Liver Transpl 2014;20:945-951.
34. Duvoux C, Roudot-Thoraval F, Decaens T, Pessione F, Badran H, Piardi T, et al.; Liver Transplantation French Study Group. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. Gastroenterology 2012;143:986-994.